🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,180 results for “Takeda Pharmaceuticals International AG” Clear

  1. TAK-583

    Takeda Pharmaceuticals International AG

    Neuralgia, Postherpetic

    phase 3 small molecule completed

    1 trial

  2. TAK-625

    Takeda Pharmaceuticals International AG

    Alagille Syndrome (ALGS)

    phase 3 small molecule completed

    1 trial

  3. TAK-625

    Takeda Pharmaceuticals International AG

    Progressive Familial Intrahepatic Cholestasis (PFIC)

    phase 3 small molecule completed

    1 trial

  4. TAK-667

    Takeda Pharmaceuticals International AG

    Hereditary Angioedema

    phase 3 small molecule completed

    1 trial

  5. TAK-672

    Takeda Pharmaceuticals International AG

    Acquired Hemophilia A

    phase 3 mab completed

    1 trial

  6. TAK-743 300 mg

    Takeda Pharmaceuticals International AG

    Hereditary Angioedema

    phase 3 small molecule completed

    1 trial

  7. TAK-755

    Takeda Pharmaceuticals International AG

    Thrombotic Thrombocytopenic Purpura (TTP)

    phase 3 mab active

    3 trials

  8. TAK-771

    Takeda Pharmaceuticals International AG

    Primary Immunodeficiency Diseases (PID)

    phase 3 small molecule completed

    2 trials

  9. TAK-771

    Takeda Pharmaceuticals International AG

    Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

    phase 3 small molecule active

    1 trial

  10. TAK-788

    Takeda Pharmaceuticals International AG

    Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  11. TAK-816

    Takeda Pharmaceuticals International AG

    Healthy Volunteers

    phase 3 mab completed

    1 trial

  12. TAK-816+ DPT-TAKEDA

    Takeda Pharmaceuticals International AG

    Immunization

    phase 3 mab completed

    1 trial

  13. TAK-861

    Takeda Pharmaceuticals International AG

    Narcolepsy Type 1

    phase 3 small molecule active

    4 trials

  14. TAK-861

    Takeda Pharmaceuticals International AG

    Narcolepsy Type 1 (NT1)

    phase 3 small molecule active

    1 trial

  15. TAK-861, TAK-861 placebo (same excipients as TAK-861)

    Takeda Pharmaceuticals International AG

    Narcolepsy with Cataplexy (Narcolepsy Type 1)

    phase 3 small molecule active

    1 trial

  16. TAK-861, TAK-861 placebo (same excipients as TAK-861), TAK-861

    Takeda Pharmaceuticals International AG

    Narcolepsy with Cataplexy (Narcolepsy Type 1)

    phase 3 small molecule active

    1 trial

  17. TAK-861, TAK-861 placebo (same excipients as TAK-861), TAK-861

    Takeda Pharmaceuticals International AG

    Narcolepsy with Cataplexy (Narcolepsy Type 1)

    phase 3 small molecule active

    1 trial

  18. TAK-875

    Takeda Pharmaceuticals International AG

    Diabetes Mellitus

    phase 3 small molecule completed

    3 trials

  19. TAK-875

    Takeda Pharmaceuticals International AG

    Diabetes Mellitus, Type 2

    phase 3 small molecule terminated

    4 trials

  20. TAK-875

    Takeda Pharmaceuticals International AG

    Diabetic Patients

    phase 3 small molecule completed

    1 trial

  21. TAK-875

    Takeda Pharmaceuticals International AG

    Type 2 Diabetes

    phase 3 small molecule terminated

    1 trial

  22. TAK-875

    Takeda Pharmaceuticals International AG

    Type 2 Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  23. TAK-881

    Takeda Pharmaceuticals International AG

    Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

    phase 3 mab active

    1 trial

  24. TAK-881

    Takeda Pharmaceuticals International AG

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab active

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources